Assessing Second-Line Treatment Strategies and Outcomes in Epidermal Growth Factor Receptor (EGFR) Oncogene-Driven Stage IV Non-Small Cell Lung Cancer, Following a First-Line EGFR-TKI Therapy.
- DOI
- 10.1002/cnr2.70428
- Published
- 2025 Dec
- Container
- Cancer reports (Hoboken, N.J.)
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/cnr2.70428,
title = {Assessing Second-Line Treatment Strategies and Outcomes in Epidermal Growth Factor Receptor (EGFR) Oncogene-Driven Stage IV Non-Small Cell Lung Cancer, Following a First-Line EGFR-TKI Therapy.},
author = {Maddula M and Decaria A and Brown B and Simes J and Boyer M and Chin V},
year = {2025},
journal = {Cancer reports (Hoboken, N.J.)},
doi = {10.1002/cnr2.70428},
url = {https://doi.org/10.1002/cnr2.70428}
}RIS
TY - JOUR TI - Assessing Second-Line Treatment Strategies and Outcomes in Epidermal Growth Factor Receptor (EGFR) Oncogene-Driven Stage IV Non-Small Cell Lung Cancer, Following a First-Line EGFR-TKI Therapy. AU - Maddula M AU - Decaria A AU - Brown B AU - Simes J AU - Boyer M AU - Chin V PY - 2025 JO - Cancer reports (Hoboken, N.J.) DO - 10.1002/cnr2.70428 UR - https://doi.org/10.1002/cnr2.70428 ER -
APA
M, M., A, D., B, B., J, S., M, B., & V, C. (2025). Assessing Second-Line Treatment Strategies and Outcomes in Epidermal Growth Factor Receptor (EGFR) Oncogene-Driven Stage IV Non-Small Cell Lung Cancer, Following a First-Line EGFR-TKI Therapy.. Cancer reports (Hoboken, N.J.). https://doi.org/10.1002/cnr2.70428
Source records
- pubmed · retrieved 2026-09-25T00:31:09.839Z
- europe-pmc · retrieved 2026-09-25T00:31:09.857Z
- doaj · retrieved 2026-09-25T00:31:09.841Z